<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452009</url>
  </required_header>
  <id_info>
    <org_study_id>C-10-151</org_study_id>
    <nct_id>NCT01452009</nct_id>
  </id_info>
  <brief_title>Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%</brief_title>
  <official_title>Three Month Safety and Efficacy Study of TRAVATAN® vs Travoprost Ophthalmic Solution, 0.004%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, observer-masked, randomized, parallel group efficacy and safety study of&#xD;
      TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004%&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Management Decision&#xD;
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: mean IOP Efficacy as measured by mean IOP</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Travoprost Ophthalmic Solution, 0.004% (New Formulation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TRAVATAN®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TRAVATAN® administered one drop once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Ophthalmic Solution, 0.004% (New Formulation)</intervention_name>
    <description>Travoprost Ophthalmic Solution, 0.004% given one drop once daily</description>
    <arm_group_label>Travoprost Ophthalmic Solution, 0.004% (New Formulation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRAVATAN®</intervention_name>
    <description>TRAVATAN® administered one drop once daily</description>
    <arm_group_label>TRAVATAN®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients 18 years of age or older&#xD;
&#xD;
          2. Either gender&#xD;
&#xD;
          3. Any race/ethnicity&#xD;
&#xD;
          4. Diagnosed with open-angle glaucoma (including patients with pseudoexfoliation and&#xD;
             pigment dispersion) or ocular hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any form of glaucoma other than open-angle glaucoma.&#xD;
&#xD;
          2. Patients with a central cornea thickness greater than 620 μm&#xD;
&#xD;
          3. Patients with Shaffer angle Grade &lt; 2&#xD;
&#xD;
          4. Patients with a cup/disc ratio greater than 0.80&#xD;
&#xD;
          5. Patients with severe central visual field loss&#xD;
&#xD;
          6. Best-Corrected Visual Acuity score worse than 55 ETDRS letters (20/80 Snellen&#xD;
             equivalent)&#xD;
&#xD;
          7. Chronic, recurrent or severe inflammatory eye disease&#xD;
&#xD;
          8. Clinically significant or progressive retinal disease&#xD;
&#xD;
          9. Other ocular pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>October 12, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <last_update_submitted>February 9, 2012</last_update_submitted>
  <last_update_submitted_qc>February 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>open angle glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

